Genrix Bio 智翔金泰
2 significant filings since 29 May 2026: 2 on new listing. The latest, on 16 Jun 2026: 首次公开发行部分限售股上市流通公告. 1 unverified report logged, the latest on 21 Sep 2026.
自 29 May 2026 起有 2 份重大公告：new listing 2 份。最新一份（16 Jun 2026）：首次公开发行部分限售股上市流通公告。记录了 1 条未经核实的报道，最新一条见于 21 Sep 2026。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 西南证券 | 杜向阳 | Unrated | 2 Sep 2026 | 1 | — |
| 国信证券 | 马千里,陈曦炳,彭思宇 | Outperform 增持 | 7 May 2026 | 2 | — |
| 中邮证券 | 盛丽华,徐智敏 | Outperform 增持 | 10 Oct 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 4 reports. 每行为该券商近十二个月的最新研报；4 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。